摘要：国际肺癌研究协会（IASLC）与欧洲肿瘤内科学会（ESMO）于2015年联合设立的海因·H·汉森奖（Heine H. Hansen Award），旨在纪念这位丹麦肺癌研究先驱、ESMO与IASLC联合创始人。该奖项每年颁发给为全球肺癌研究与教育作出突出贡献的学

国际肺癌研究协会（IASLC）与欧洲肿瘤内科学会（ESMO）于2015年联合设立的海因·H·汉森奖（Heine H. Hansen Award），旨在纪念这位丹麦肺癌研究先驱、ESMO与IASLC联合创始人。该奖项每年颁发给为全球肺癌研究与教育作出突出贡献的学者，今年被授予在非小细胞肺癌（NSCLC）分类体系构建及肺癌诊疗指南制定方面有卓越贡献的Keith Kerr教授。Keith Kerr是苏格兰阿伯丁大学医学院和阿伯丁皇家医院的顾问病理学家及病理学教授，专业领域是胸部病理学，尤其是肺癌。他在获奖主题报告中指出：“随着精准医学和人工智能（AI）的发展，肺癌病理学家与临床医生之间长期存在的隔阂正在消弭，病理学分类成果正以创新方式融入临床决策。”

祝贺您获得Heine H. Hansen奖。能否分享一下您获奖后的感想，简要介绍获奖主题演讲的核心观点？

Dr. Kerr：获得这个奖项对我来说非常荣幸，尤其是作为一名病理学家，能够获得来自肿瘤学术机构（IASLC和ESMO）的奖项意义非凡。多年前我在接受胸部病理学培训时，我的导师就非常明确地指出，除了病理学本身，了解我所研究疾病的临床诊疗也至关重要。我一直努力保持对临床诊疗动态的关注，这对病理学家非常重要。因此，能够获得肿瘤学机构颁发的奖项对我而言意义重大。

我的获奖演讲主要强调两个方面。首先是Heine H. Hansen对肺癌及其治疗（尤其是小细胞癌领域）的深远影响。我的年龄足以让我认识他，虽然从未见过他本人，但我会记住他的成果。我的病理学导师与他相识，并密切关注他的研究工作。演讲的另一重点是治疗学发展对近三四十年病理学与诊断技术进步的重要推动作用。尽管病理学家传统上更关注做出诊断，但过去某些诊断并不一定与患者治疗密切相关，然而这种局面在肺癌领域已发生扭转。这正是我职业生涯中见证并希望传递的故事。

Dr Kerr: Well, thank you very much for that. It really is a great honor to receive this award, especially for me as a pathologist to receive an award from an oncology organization is really very special to me. When I was trained a long time ago in thoracic pathology, my mentor was very clear that it was very important for me to be aware of the clinical aspects of the diseases that I was dealing with, as well as the pathology. I have always tried to be clinically aware of what is going on, and I think that is really important for a pathologist. So, it really means a lot to me to get this award from such an organization.

I think the key points that I tried to emphasize in my talk accepting the Heine Hansen Award were really two-fold. One was the influence Heine Hansen had on certain aspects of lung cancer and its treatment, particularly in the arena of small cell carcinoma. I am old enough to remember Heine Hansen. I never met him, but I remember him from his work. My pathology teacher knew Heine Hansen and followed his work carefully. The other main point of my talk was how far pathology and diagnostics have evolved over the last 30 or 40 years, largely driven by therapeutics. Although we pathologists tend to concentrate on making a diagnosis, sometimes that diagnosis is not necessarily very relevant for the treatment of the patient, but that has all changed in lung cancer in particular. That is really the story I tried to tell from over the course of my career.

您对2025年欧洲肺癌大会（ELCC）哪些讨论和研究最感兴趣？

Dr. Kerr：本届ELCC有很多非常精彩的演讲和研究。由于分会场并行，我未能全部参与，但仍注意到几个亮点领域：

1.治疗进展：有很多新药和新组合正在涌现，最引人注目的是MARIPOSA研究，其结果显示在EGFR突变NSCLC一线治疗中，埃万妥单抗（amivantamab）联合兰泽替尼（lazertinib）的疗效被证明优于奥希替尼单药，甚至可能优于奥希替尼联合化疗。对EGFR突变NSCLC患者来说，增加了一种新的联合方案，意义重大，尽管其毒性问题引发热议，也有一些临床试验也在探索如何降低毒性。

2.人工智能（AI）应用：一些会场探讨了AI将如何影响肺癌治疗的各个方面（包括病理学）。虽然该领域存在炒作成分且资本大量涌入，但人们看到了很多机会。有时，我会担心新技术的快速普及，而我们还没有找到最佳的利用方式。这些新技术真的会对我们有帮助吗？AI看起来会有帮助，可能非常有趣且功能强大，但具体的技术应用路径需进一步探索。

3.病理诊断：2025 ELCC的一个会场讨论了诊断服务的问题，以及如何在世界各地（尤其是在资源匮乏的地区）提供诊断服务，尤其是基因分型。我们有时会忽视一个事实：并非每个人都能负担广泛基因检测、高端技术解决方案以及液体活检。这些检测费用昂贵，但提供的信息可能远远超出了治疗患者的实际需求。我有时觉得，尤其是在资源受限的地方，或许资源更应投入在“简单步骤诊断”，因其已能提供大部分必要信息（不是全部）。有时，我们会忽略这种"简约智慧"的价值。

Dr. Kerr: This year at ELCC 2025, there have been lots of very good presentations and studies. Of course, because of our parallel sessions, I haven’t been able to get to everything, but I have attended a few. I think there are 2 or 3 areas that stand out to me for different reasons. In terms of therapeutics, obviously there is a lot going on with new drugs and new combinations coming along. One of the standout discussions at this meeting has been the presentation of the MARIPOSA data where amivantamab and lazertinib have been shown in first-line to be almost superior as a combination to osimertinib in EGFR-mutated tumors, and probably also superior to osimertinib plus chemotherapy. This is a new combination for our EGFR-mutated patients, which is potentially very significant. There are issues with toxicity, and this was the subject of a great deal of discussion and also some clinical trials trying to ameliorate that toxicity. That is one thing. We had a very interesting session on how artificial intelligence is potentially going to impact on all sorts of aspects of lung cancer care, including pathology. There is a lot of hype around this area. There is a lot of investment and money being poured into this. I am sure people see a lot of opportunities. Sometimes I get concerned about the rapid adoption of new technology when we haven’t figured out the best way to use that technology. Is it really going to help us? I does look as if it will, but exactly how that looks remains to be determined, I think. But it is certainly very interesting and potentially very powerful. The last thing, and this is relevant to my area – the issue of delivering diagnostics was discussed in one of the sessions, and how we deliver diagnostics, and especially genotyping, in different parts of the world, especially in parts of the world where there are challenges around resources. I think sometimes we lose sight of the fact that not everyone can afford extensive genotyping, very high-end technology solutions, liquid biopsy testing. These are expensive tests. They often deliver far more information than what is actually required to treat the patient. I sometimes feel, especially in places where resources are constrained, that those resources may be better invested in the simpler diagnostic steps, which still liver most, if not all, of the information that is required for the patient. Sometimes, we lose sight of that simplicity.

《肿瘤瞭望》在ELCC现场报道

来源：肿瘤瞭望